Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Validation Study Under CLIA-compliant SOPs for the Proprietary Rectal and Anal Cancer Protein Expression Assays

NCT02407561 is registered in ClinicalTrials.gov with Castle Biosciences Incorporated as lead sponsor.

NCT NCT02407561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02407561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Validation Study Under CLIA-compliant SOPs for the Proprietary Rectal and Anal Cancer Protein Expression Assays
Lead sponsor
Castle Biosciences Incorporated
Phase
Observational
Overall status
Terminated
Start date
February 28, 2015
Completion date
July 31, 2016
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anal adenocarcinoma, anal squamous cell carcinoma, rectal adenocarcinoma